ALKBH7 and glioblastoma: In the intracranial glioblastoma model, downregulation of ALKBH7 in SNB19 cells resulted in less intracerebral tumor proliferation in size and low expression of APNG after concurrent TMZ treatment (Figure 7C), suggesting that downregulation of ALKBH7 increased the therapeutic effect of TMZ in mice against intracranial proliferation of glioblastomas.